<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>ATROPINE SULFATE - atropine sulfate injection </strong><br>General Injectables &amp; Vaccines, Inc<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>Atropine Sulfate Injection, USP
FOR IM, IV, OR SC USE
Rx Only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<br>Atropine Sulfate Injection, USP is a sterile solution of atropine sulfate in Water for Injection. Each mL contains Atropine Sulfate 0.4 mg; Sodium Chloride 9 mg; Benzyl Alcohol 9 mg; Water for Injection qs; pH may be adjusted with Sulfuric Acid if necessary. pH 3.0-6.5.<br><br>Atropine Sulfate Injection, USP may be given intramuscularly, intravenously or subcutaneously. Atropine is a white crystalline alkaloid which may be extracted from belladonna root or may be produced synthetically. It is used as atropine sulfate because this compound has much greater solubility.<br><br>Atropine sulfate is an anticholinergic drug. The empirical formula of atropine sulfate is (C17H23NO3)2.H2SO4.H2O.<br><br>The structural formula is:<br><br><div class="Figure"><img alt="Formula1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baf1529e-737d-4cbc-9111-6e5d89525051&amp;name=Formula1.jpg"></div>
<br><br><br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<br>The most important therapeutic action of atropine is the inhibition of smooth muscle and glands innervated by postganglionic cholinergic nerves. It also has central nervous system activity, which may be stimulating or depressing depending upon the dose.<br><br>Following the administration of usual clinical doses, atropine produces stimulation of the medulla and higher cerebral centers. This effect is manifested by mild central vagal excitation and moderate respiratory stimulation. Atropine sulfate also acts peripherally as a competitive antagonist of the muscarinic actions of acetycholine. It does not prevent the release of acetylcholine but antagonizes the effect of acetylcholine on the effector cells. These actions include vasodilation, drying of the mouth, an increase in the pulse rate, inhibition of contractions of the gastrointestinal tract, ureter, and bladder, and reduction of salivary, bronchial, gastric and sweat gland secretions. Following clinical and larger doses, atropine sulfate causes dilation of the pupils and <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of accommodation and, in narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, can increase intraocular pressure.<br>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<br>Atropine sulfate is given parenterally as a preanesthetic medication to decrease <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> and bronchial secretions. It is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and <span class="product-label-link" type="condition" conceptid="4291807" conceptname="Biliary colic">biliary colic</span>, atropine sulfate given with morphine may be indicated. Atropine sulfate is indicated for relaxation of the upper gastrointestinal tract and colon during hypotonic radiography.<br><br>Atropine is used as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and in <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> by the organic phosphate <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors found in certain insecticides and by chemical warfare "nerve gases". Large doses relieve the muscarine-like symptoms and some of the central nervous system manifestations.<br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<br>Conditions at which inhibition of postganglionic cholinergic nerves are undesirable, such as <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Also contraindicated in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, because the parenteral dose which might relieve <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> would have an excessive drying effect upon mucous plugs in the bronchi. <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Prostatic hypertrophy</span>, while not a contraindication, requires special attention to signs of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.<br>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<br>Atropine is a highly potent drug and due care is essential to avoid overdosage, especially with intravenous administration. Pediatric populations are more susceptible than adults to the toxic effects of anticholinergic agents.<br><br>Atropine I.V. decreased the rate of mexiletine absorption without altering the relative oral bioavailability; this delay in mexiletine absorption was reversed by the combination of atropine and intravenous metoclopramide during pretreatment for anesthesia. Atropine is not removed by dialysis.<br><br>This drug is effective in very low dosage and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may cause permanent damage or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, especially in children.<br><br>This product contains Benzyl Alcohol which has been associated with a fatal <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome in infants and neonates.<br>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<br><span class="Bold">General<br></span>Doses of 0.5 to 1 mg atropine are mildly stimulating to the CNS. Larger doses may produce mental disturbances; still larger doses are depressing. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> from atropine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, though rare, is usually due to <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the medullary centers.<br><br><span class="Bold">Information for Patients<br></span>Atropine causes dryness of the mouth, and when used with other drugs that can cause dryness of the mouth, the effect is additive. Patients receiving chronic treatment can develop <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, and they should not be involved in activities that require good and clear vision.<br><br><span class="Bold">Drug Interactions<br></span>Atropine, by slowing gastric emptying and gastrointestinal mobility, may interfere with the absorption of other medications. The effect of atropine on dryness of the mouth may be increased if it is given with other drugs that have anticholinergic action.<br><br><span class="Bold">Pregnancy Category C<br></span>Animal reproduction studies have not been conducted with atropine sulfate. It is also not known whether atropine sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Atropine sulfate should be given to a pregnant woman only if clearly needed.<br><br><span class="Bold">Nursing Mothers<br></span><span class="Bold"></span>Caution should be exercised when atropine sulfate is administered to a nursing mother.<br>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<br>Individual tolerance varies greatly, but these systemic doses are likely to produce the following effects:<br><br>0.5 mg -                Slight dryness of nose and mouth, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.<br><br>1 mg -                    Greater dryness of nose and mouth, with <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>; slowing, then acceleration of heart; slight <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>.<br><br>2 mg -                    Very <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, with <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, slight blurring of near vision.<br><br>5 mg -                    Increase in the above symptoms plus disturbance of speech, difficulty in swallowing, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, hot, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> with <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>.<br><br>10 mg and over -    Above symptoms to extreme degree, plus <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.<br><br>65 mg -                     May be fatal.<br><br>A scarlatiniform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may occur. Atropine may produce <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, particularly in children, through inhibition of heat loss by evaporation. Although large doses of atropine may cause an alarming condition, recovery is usual.<br><br><br>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<br>Toxic doses from atropine are not uncommon, especially in children.<br><br><span class="Bold">Symptoms<br></span>The principle manifestations of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> with atropine are <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.<br><br><span class="Bold">Treatment<br></span>In the treatment of atropine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, respiratory assistance and symptomatic support are indicated. Physostigmine salicylate, 1 to 5 mL of a dilution containing 1 mg per 5 mL of saline, should be administered intravenously. Administer the smaller dose in children and administer in not less than 2 minutes. Monitor with ECG. Medication can be repeated every 5 minutes for a total dose of 2 mg in children and every 30 minutes for a total dose of 6 mg in adults.<br><br>The fatal dose of atropine in children may be as low as 10 mg. In an adult, recovery after 1,000 mg of atropine sulfate has been reported. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> is usually due to <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the medullary centers. The fatality rate is less than 1%. If the patient survives 24 hours, they will probably recover.<br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<br>The usual dose of atropine sulfate is 0.4 to 0.6 mg. Suggested dosages for pediatric patients are as follows:<br><br><a name="i24e640b6-cd52-4a5c-8f77-9b5d238782c9"></a><table width="100%"><tbody class="Headless">
<tr class="First">
<td>7 - 16 lbs. - 0.1 mg<br>
</td>
<td>40 - 65 lbs. - 0.3 mg<br>
</td>
</tr>
<tr>
<td>17 - 24 lbs. - 0.15 mg<br>
</td>
<td>65 - 90 lbs. - 0.4 mg<br>
</td>
</tr>
<tr class="Last">
<td>24 - 40 lbs. - 0.2 mg<br>
</td>
<td>Over 90 lbs. - 0.4 to 0.6 mg<br>
</td>
</tr>
</tbody></table>
<span class="Bold">Table of Dosage Equivalents<br></span>Atropine Sulfate Solution (mL required)<br><br><a name="i0d5ec96f-185e-4999-8a82-7f50a7c0faa1"></a><table width="100%"><tbody class="Headless">
<tr class="First">
<td>mg required<br>
</td>
<td>1 mg per mL<br>
</td>
<td>0.4 mg per mL<br>
</td>
</tr>
<tr>
<td>1<br>
</td>
<td>1<br>
</td>
<td><br></td>
</tr>
<tr>
<td>0.80<br>
</td>
<td>0.80<br>
</td>
<td><br></td>
</tr>
<tr>
<td>0.60<br>
</td>
<td>0.60<br>
</td>
<td><br></td>
</tr>
<tr>
<td>0.50<br>
</td>
<td>0.50<br>
</td>
<td><br></td>
</tr>
<tr>
<td>0.40<br>
</td>
<td>0.40<br>
</td>
<td>1<br>
</td>
</tr>
<tr>
<td>0.30<br>
</td>
<td>0.30<br>
</td>
<td>0.75<br>
</td>
</tr>
<tr>
<td>0.25<br>
</td>
<td>0.25<br>
</td>
<td>0.63<br>
</td>
</tr>
<tr>
<td>0.20<br>
</td>
<td>0.20<br>
</td>
<td>0.50<br>
</td>
</tr>
<tr>
<td>0.18<br>
</td>
<td>0.18<br>
</td>
<td>0.45<br>
</td>
</tr>
<tr>
<td>0.15<br>
</td>
<td>0.15<br>
</td>
<td>0.38<br>
</td>
</tr>
<tr>
<td>0.12<br>
</td>
<td>0.12<br>
</td>
<td>0.30<br>
</td>
</tr>
<tr class="Last">
<td>0.10<br>
</td>
<td>0.10<br>
</td>
<td>0.25<br>
</td>
</tr>
</tbody></table>These doses may be exceeded in certain cases.<br>For hypotonic radiography of the gastrointestinal tract, the usual adult dose is 1 mg intramuscularly.<br>Adults suspected of contact with organic phosphorous insecticides of the parathion type should be given atropine sulfate 0.8 mg intramuscularly. If an atropine effect is not apparent within 30 minutes or if definite symptoms of the <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> occur (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, pupillary constriction, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculations</span> of eyelids and tongue, jerky ocular movements and excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> and bronchial secretion), atropine sulfate 2 mg should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to 2 or 3 times of this dose (4 to 6 mg) may be required in severe cases.<br><span class="Bold">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</span><br><br><br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<br>Atropine Sulfate Injection, USP is available in the following:<br><br><span class="Bold">0.4 mg/mL<br></span>    20 mL multiple dose vial packaged in 10s (NDC 0641-6006-10)<br>Use only if solution is clear and seal intact.<br><span class="Bold">Store at 20°-25°C (68°-77°F), excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature].<br></span>To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceutical Corp. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or <span class="Underline">www.fda.gov/medwatch</span>.<br>For Product Inquiry call 1-877-845-0689.<br><br>Manufactured by:<br>WEST-WARD<br>PHARMACEUTICALS<br>Eatontown, NJ 07724 USA<br>Revised July 2011    462-416-01<br><span class="Bold"><br></span>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>Sample Package Label</h1>
<p class="First"><img alt="Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=baf1529e-737d-4cbc-9111-6e5d89525051&amp;name=Label1.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ATROPINE SULFATE 		
					</strong><br><span class="contentTableReg">atropine sulfate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52584-029(NDC:0641-6006)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Atropine Sulfate</strong> (Atropine) </td>
<td class="formItem">Atropine Sulfate</td>
<td class="formItem">0.4 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52584-029-01</td>
<td class="formItem">1  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">05/08/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>General Injectables &amp; Vaccines, Inc
							(108250663)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f7aa80fe-40ed-4190-96ae-08a1213c2a91</div>
<div>Set id: baf1529e-737d-4cbc-9111-6e5d89525051</div>
<div>Version: 1</div>
<div>Effective Time: 20120508</div>
</div>
</div> <div class="DistributorName">General Injectables &amp; Vaccines, Inc</div></p>
</body></html>
